1. Home
  2. NUR vs FEMY Comparison

NUR vs FEMY Comparison

Compare NUR & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NUR

Nuran Wireless Inc. Common Shares

N/A

Current Price

$0.79

Market Cap

25.2M

Sector

N/A

ML Signal

N/A

FEMY

Femasys Inc.

HOLD

Current Price

$1.69

Market Cap

22.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NUR
FEMY
Founded
N/A
2004
Country
Canada
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
25.2M
22.4M
IPO Year
2016
2021

Fundamental Metrics

Financial Performance
Metric
NUR
FEMY
Price
$0.79
$1.69
Analyst Decision
Buy
Analyst Count
0
3
Target Price
N/A
★ $14.33
AVG Volume (30 Days)
★ 211.8K
92.3K
Earning Date
08-28-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 44.71
EPS
★ N/A
N/A
Revenue
N/A
★ $2,293,313.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$328.45
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 40.77
52 Week Low
$0.60
$0.29
52 Week High
$7.72
$6.29

Technical Indicators

Market Signals
Indicator
NUR
FEMY
Relative Strength Index (RSI) 34.54 33.65
Support Level $0.60 $0.40
Resistance Level $0.85 $3.21
Average True Range (ATR) 0.09 0.21
MACD 0.02 -0.02
Stochastic Oscillator 32.12 32.22

Price Performance

Historical Comparison
NUR
FEMY

About FEMY Femasys Inc.

Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.

Share on Social Networks: